MoonLake Immunotherapeutics (MLTX) has provided an update.
MoonLake Immunotherapeutics recently announced substantial advancements in the treatment of active psoriatic arthritis with their Nanobody sonelokimab, alongside other updates during their R&D Day on March 10, 2024. The company has also published the presentation from this event on their website, signaling potential interest for investors tracking innovative developments in the biopharmaceutical sector.
Learn more about MLTX stock on TipRanks’ Stock Analysis page.
